Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H11Cl2NO2 |
Molecular Weight | 296.149 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl
InChI
InChIKey=DCOPUUMXTXDBNB-UHFFFAOYSA-N
InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
Molecular Formula | C14H11Cl2NO2 |
Molecular Weight | 296.149 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/pro/diclofenac.htmlCurator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25963327 | https://www.ncbi.nlm.nih.gov/pubmed/20470236 | http://www.pharmaceutical-journal.com/news-and-analysis/news/diclofenac-a-useful-drug-that-may-now-be-entering-its-twilight-years/11121261.article
Sources: https://www.drugs.com/pro/diclofenac.html
Curator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25963327 | https://www.ncbi.nlm.nih.gov/pubmed/20470236 | http://www.pharmaceutical-journal.com/news-and-analysis/news/diclofenac-a-useful-drug-that-may-now-be-entering-its-twilight-years/11121261.article
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. In addition diclofenac can inhibit the thromboxane-prostanoid receptor, affect arachidonic acid release and uptake, inhibit lipoxygenase enzymes, and activate the nitric oxide-cGMP antinociceptive pathway. Other novel mechanisms of action may include the inhibition of substrate P, inhibition of peroxisome proliferator activated receptor gamma (PPARgamma), blockage of acid-sensing ion channels, alteration of interleukin-6 production, and inhibition of N-methyl-D-aspartate (NMDA) receptor hyperalgesia. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. The drug's likely impact on the Asian vulture population was widely reported. The dramatic mortality was attributed largely to renal failure caused by exposure to diclofenac in livestock carcasses on which the birds fed. Although not the most endearing species, vultures are important environmental scavengers and, since veterinary use of diclofenac was stopped in the region in 2006, the decline in vulture numbers has slowed.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3085489
Curator's Comment:: reference retrieved from http://www.pharmaceutical-journal.com/news-and-analysis/news/diclofenac-a-useful-drug-that-may-now-be-entering-its-twilight-years/11121261.article
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.97 nM [IC50] | |||
0.037 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DICLOFENAC SODIUM Approved UseDiclofenac Sodium Extended-release Tablets are indicated:
•For relief of the signs and symptoms of osteoarthritis
•For relief of the signs and symptoms of rheumatoid arthritis |
|||
Primary | DICLOFENAC SODIUM Approved UseDiclofenac Sodium Extended-release Tablets are indicated:
•For relief of the signs and symptoms of osteoarthritis
•For relief of the signs and symptoms of rheumatoid arthritis |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
902 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
302 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
12.5 mg 3 times / day steady-state, oral dose: 12.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
749 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
25 mg 3 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1208 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
12.5 mg 3 times / day steady-state, oral dose: 12.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
609 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
25 mg 3 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
12.5 mg 3 times / day steady-state, oral dose: 12.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.87 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19531931 |
25 mg 3 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DICLOFENAC plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2.3 h |
unknown, oral |
DICLOFENAC serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
unknown, oral |
DICLOFENAC serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg/mL single, intravenous Dose: 75 mg/mL Route: intravenous Route: single Dose: 75 mg/mL Sources: |
healthy, 18 - 53 years Health Status: healthy Age Group: 18 - 53 years Sex: M+F Sources: |
|
50 mg single, oral |
healthy, 21-51 years n = 24 Health Status: healthy Age Group: 21-51 years Sex: M+F Population Size: 24 Sources: |
Other AEs: Nephrotoxicity... |
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Disc. AE: Drowsiness, Lethargy... AEs leading to discontinuation/dose reduction: Drowsiness Sources: Lethargy Nausea Vomiting Epigastric pain |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nephrotoxicity | 50 mg single, oral |
healthy, 21-51 years n = 24 Health Status: healthy Age Group: 21-51 years Sex: M+F Population Size: 24 Sources: |
|
Drowsiness | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Epigastric pain | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Lethargy | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Nausea | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Vomiting | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: |
unknown, adult Health Status: unknown Age Group: adult Sex: unknown Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate | ||||
no | ||||
no | ||||
no | ||||
no | ||||
strong | ||||
weak | ||||
weak | ||||
weak | ||||
yes [Ki 11 uM] | ||||
yes [Ki 19 uM] | ||||
yes [Ki 28 uM] | ||||
yes [Ki 52 uM] | ||||
yes [Ki 60 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
minor | ||||
moderate | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Nimesulide, a balanced drug for the treatment of osteoarthritis. | 2001 |
|
Celecoxib versus diclofenac in the management of osteoarthritis of the knee. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Review: uveitis and immunosuppressive drugs. | 2001 Apr |
|
Cataflam-induced esophageal ulceration. | 2001 Apr |
|
Anti-inflammatory drugs. IX. Hydrated diethylammonium (2-(2,6-dichlorophenylamino)phenyl)acetate (HDEA.D.H2O). | 2001 Apr |
|
Efficacy of peripheral morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery patients. | 2001 Apr |
|
Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. | 2001 Apr |
|
Influence of electrical and chemical factors on transdermal iontophoretic delivery of three diclofenac salts. | 2001 Apr |
|
The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. | 2001 Apr |
|
Tramadol vs. diclofenac for posttonsillectomy analgesia. | 2001 Apr |
|
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. | 2001 Apr |
|
Equivalence of generic and brand-name ophthalmic products. | 2001 Apr 1 |
|
Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. | 2001 Apr 28 |
|
Inhibition of COX in ocular tissues: an in vitro model to identify selective COX-2 inhibitors. | 2001 Feb |
|
Comparative study of diclofenac sodium and paracetamol for treatment of pain after adenotonsillectomy in children. | 2001 Feb |
|
Diclofenac-induced gastric mucosal fluorescence in rats. | 2001 Feb |
|
Determination of diclofenac sodium, flufenamic acid, indomethacin and ketoprofen by LC-APCI-MS. | 2001 Feb |
|
Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers. | 2001 Feb |
|
Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. | 2001 Feb |
|
Thermographic imaging of postoperative inflammation modified by anti-inflammatory pretreatment. | 2001 Feb |
|
Tacholiquine inhalation and aspirin-induced asthma. | 2001 Feb |
|
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | 2001 Feb |
|
Effects of anti-inflammatory drugs following cataract extraction. | 2001 Feb |
|
[Topical administration is better than oral administration]. | 2001 Feb 1 |
|
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. | 2001 Feb 23 |
|
Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet. | 2001 Feb 23 |
|
A comparative experimental study of the effects of diclofenac and ketoprofen on the small-bowel mucosa of canines. | 2001 Jan |
|
Truth and consequences. | 2001 Jan |
|
Truth and consequences. | 2001 Jan |
|
Effects of diclofenac in the rat tail ischaemia--reperfusion injury model of acute hyperalgesia. | 2001 Jan |
|
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. | 2001 Jan |
|
Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model. | 2001 Jan |
|
Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. | 2001 Jan |
|
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). | 2001 Jan 29 |
|
[Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database]. | 2001 Jan-Feb |
|
Is diclofenac a valuable CYP2C9 probe in humans? | 2001 Jan-Feb |
|
Analgesic effect of epidural neostigmine after abdominal hysterectomy. | 2001 Mar |
|
Perioperative intravenous flurbiprofen reduces postoperative pain after abdominal hysterectomy. | 2001 Mar |
|
Docetaxel extravasation. | 2001 Mar |
|
[Effect of tobramycin with topical diclofenac on arachidonic acid in endotoxin-induced uveitis]. | 2001 Mar |
|
Physical incompatibility between atracurium and intravenous diclofenac. | 2001 Mar |
|
Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. | 2001 Mar |
|
Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. | 2001 Mar 30 |
|
Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. | 2001 May |
|
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. | 2001 May |
|
Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. | 2001 May |
Patents
Sample Use Guides
For topical dosage form (gel):
For actinic keratosis using Solaraze® 3% gel:
Adults—Apply to affected skin area two times a day.
Children—Use and dose must be determined by your doctor.
For osteoarthritis of the hands, elbows, or wrists using Voltaren® 1% gel:
Adults—Apply 2 grams to the affected skin areas four times a day (a total of 8 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Use the enclosed dosing card to measure the appropriate dose.
Children—Use and dose must be determined by your doctor.
For osteoarthritis of the knees, ankles, or feet using Voltaren® 1% gel:
Adults—Apply 4 grams to the affected skin areas four times a day (a total of 16 grams each day). However, the total dose should not exceed 32 grams per day over all affected joints. Use the enclosed dosing card to measure the appropriate dose.
Children—Use and dose must be determined by your doctor.
For topical dosage form (solution):
For osteoarthritis of the knee:
Adults—40 drops (10 drops at a time) on each affected knee four times a day.
Children—Use and dose must be determined by your doctor.
For transdermal dosage form (skin patch):
For acute pain:
Adults—One patch applied to the painful area two times a day.
Children—Use and dose must be determined by your doctor.
For oral dosage form (capsules):
For acute pain:
Adults—18 or 35 milligrams (mg) three times a day.
Children—Use and dose must be determined by your doctor.
For osteoarthritis:
Adults—35 milligrams (mg) three times a day.
Children—Use and dose must be determined by your doctor.
For oral dosage forms (delayed-release tablets, enteric-coated tablets):
For ankylosing spondylitis:
Adults—25 milligrams (mg) four times a day, with an extra 25 mg dose at bedtime if necessary.
Children—Use and dose must be determined by your doctor.
For osteoarthritis:
Adults—50 milligrams (mg) two or three times a day, or 75 mg two times a day.
Children—Use and dose must be determined by your doctor.
For rheumatoid arthritis:
Adults—50 milligrams (mg) three or four times a day, or 75 mg two times a day.
Children—Use and dose must be determined by your doctor.
For oral dosage form (immediate-release tablets):
For osteoarthritis:
Adults—50 milligrams (mg) two or three times a day.
Children—Use and dose must be determined by your doctor.
For pain or menstrual cramps:
Adults—50 milligrams (mg) three times a day. Your doctor may direct you to take 100 mg for the first dose only.
Children—Use and dose must be determined by your doctor.
For rheumatoid arthritis:
Adults—50 milligrams (mg) three or four times a day.
Children—Use and dose must be determined by your doctor.
For oral dosage form (solution):
For migraine headaches:
Adults—One packet (50 milligrams) as a single, one time dose.
Children—Use and dose must be determined by your doctor.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22330146
Acute (24 h) diclofenac toxicity in a range of (10-1000 μM) concentrations was assesed in primary human hepatocytes. The chronic (9 repeated doses) toxicity at one clinically relevant and another higher concentration (6.4 and 100 μM) was also tested. Acute 24 h assessment revealed toxicity only for the highest tested concentration (1 mM). Upon repeated dose exposure, toxic effects were observed even at a low, clinically relevant concentration (6.4 μM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 14:26:58 UTC 2021
by
admin
on
Sat Jun 26 14:26:58 UTC 2021
|
Record UNII |
144O8QL0L1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M01AB05
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-ATC |
S01BC03
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-ATC |
S01CC01
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
CFR |
21 CFR 524.590
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-ATC |
D11AX18
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-VATC |
QD11AX18
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
NDF-RT |
N0000175722
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-ATC |
M01AB55
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
LIVERTOX |
297
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-VATC |
QM02AA15
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-VATC |
QS01CC01
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-ATC |
M02AA15
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-VATC |
QM01AB05
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
WHO-VATC |
QS01BC03
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00586
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
865
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
7234
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
3355
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | RxNorm | ||
|
3270
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
Diclofenac
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
D004008
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
15307-86-5
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
15307-86-5
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
CHEMBL139
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
144O8QL0L1
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
DICLOFENAC
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
M4361
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | Merck Index | ||
|
SUB07092MIG
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
239-348-5
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
3033
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
2714
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY | |||
|
C28985
Created by
admin on Sat Jun 26 14:26:59 UTC 2021 , Edited by admin on Sat Jun 26 14:26:59 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
POTENT
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3'-hydroxy-diclofenac
MINOR
|
||
|
METABOLITE -> PARENT |
CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3'-hydroxy-diclofenac
MINOR
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE LESS ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |